Piper Jaffray analyst Charles Duncan lowered his price target for Neurocrine Biosciences to $68 after the company's Phase 2a study of Ingrezza in pediatric Tourette's missed the primary endpoint in its first controlled trial. The analyst, however, remains confident that the drug will demonstrate efficacy and reach the market in pediatric Tourette's. The lack of a clear signal means more time will be required, which pushes sales for the indication back to 2022 from 2021, Duncan tells investors in a research note. He reiterates an Overweight rating on Neurocrine.